Andreas Schirbel

Oberdürrbacher Str. 6
Wuerzburg, BY 97080, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Continuous flow-through steady state system for in vitro characterization of CYP11B2 inhibitors-Impact on enzyme kinetics of steroidogenesis.

Continuous flow-through steady state system for in vitro characterization of CYP11B2 inhibitors-Impact on enzyme kinetics of steroidogenesis.

Journal: The Journal of steroid biochemistry and molecular biology

Published: November 11, 2024

Combined [18F]Fluorodeoxyglucose PET and [123I]Iodometomidate-SPECT for diagnostic evaluation of indeterminate adrenal neoplasias-the cross-sectional diagnostic test accuracy study FAMIAN.

Combined [18F]Fluorodeoxyglucose PET and [123I]Iodometomidate-SPECT for diagnostic evaluation of indeterminate adrenal neoplasias-the cross-sectional diagnostic test accuracy study FAMIAN.

Journal: EBioMedicine

Published: October 07, 2024

Exploring Theranostic Avenues in Adrenocortical Carcinoma Using Chemokine Receptor and Prostate-Specific Membrane Antigen-Directed PET/CT.

Exploring Theranostic Avenues in Adrenocortical Carcinoma Using Chemokine Receptor and Prostate-Specific Membrane Antigen-Directed PET/CT.

Journal: Clinical nuclear medicine

Published: February 13, 2024

Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma.

Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: January 19, 2024

Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma.

Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 14, 2023

Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma.

Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma.

Journal: Endocrine

Published: October 05, 2023

CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology.

CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology.

Journal: European journal of nuclear medicine and molecular imaging

Published: September 03, 2023

Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [18F]FDG.

Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [18F]FDG.

Journal: American journal of nuclear medicine and molecular imaging

Published: August 18, 2023

Fluorinated aldosterone synthase (CYP11B2)-inhibitors for differential diagnosis between bilateral and unilateral conditions of primary aldosteronism.

Fluorinated aldosterone synthase (CYP11B2)-inhibitors for differential diagnosis between bilateral and unilateral conditions of primary aldosteronism.

Journal: Bioorganic & medicinal chemistry letters

Published: August 14, 2023

Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors.

Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors.

Journal: Clinical nuclear medicine

Published: May 11, 2023

Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer.

Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer.

Journal: Clinical nuclear medicine

Published: February 08, 2023

Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients.

Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 02, 2023

Showing 1-12 of 89

Last Updated: 09/26/2026